2010 Annual Scientific Meeting and Exposition 2010 Annual ...

More documents

Recommendations

Info

MAY 2Satellite SymposiumSunday Evening8:00 PM – 9:30 PM • Trianon BallroomExploring the Future of CombinationAntihypertensive Therapy: Is There a Limit to theNumber of Drugs in a Fixed-Dose Combination?Chairperson: Suzanne Oparil, MD, Birmingham, ALProgram Agenda:8:00 PM Welcome and Introductory RemarksSuzanne Oparil, MD8:05 PM Recent Clinical Trial Evidence on CombinationAntihypertensive TherapySuzanne Oparil, MD8:25 PM Combination Antihypertensive Therapy:What Are the Options and How Do We Use Them?Jan N. Basile, MD, Charleston, SC8:45 PM Triple Combinations and Beyond: What Is theFuture of Fixed-Dose Therapy?C. Venkata Ram, MD, Dallas, TX9:05 PM Optimizing the Use of Combination Therapy:A Case-Study-Illustrated DiscussionPanel Presentation – All Faculty9:25 PM Concluding RemarksSuzanne Oparil, MDLearning Objectives:• Describe hypertensive treatment practices inpatients with uncontrolled BP• Discuss the role of aggressive combinationtherapy to help achieve optimal BP control inpatients with difficult-to-treat hypertension• Describe the pharmacokinetic differences amongantihypertensive combination regimens• Understand the relative benefits of variousantihypertensive combinationsDinner will be served at 7:30 PM in theTrianon Ballroom.Supported by an educational grant from Daiichi Sankyo Inc.80
Monday Morning MAY 3Satellite Symposium6:00 AM - 7:30 AM • Trianon BallroomTargeting Endothelial Dysfunction in HypertensiveCardiovascular Disease: Why, When, and HowChairperson: Thomas D. Giles, MD, New Orleans, LAProgram Agenda:6:00 AM Introduction: New Evidence for Targeting CriticalMechanisms in Hypertensive Heart DiseaseThomas D. Giles, MD6:25 AM Race-Specific Differences in EndothelialDysfunction: Relevance to Management ofHypertensionR. Preston Mason, PhD, Boston, MA6:50 AM Targeting Endothelial Dysfunction in theManagement of Cardiovascular DiseaseAlan H. Gradman, MD, Pittsburgh, PA7:15 AM Panel Discussion and Concluding RemarksThomas D. Giles, MDLearning Objectives:• Describe the role of nitric oxide in endothelialdysfunction and in the pathogenesis ofhypertension, and hypertensive cardiovasculardisease, including LVH and heart failure• Evaluate the relationship between oxidative stressand endothelial function and its relevance to themanagement of hypertensive patients• Identify pre-clinical and clinical evidencesupporting the concept that there are race-baseddifferences in endothelial function which mayhave clinical ramifications• Analyze the pharmacologic differences amongβ-blockers, including those with vasodilatingproperties, and outline the evidence for theclinical impact of these properties, especially ontolerability and efficacyBreakfast will be served at 5:45 AM in theTrianon Ballroom.Supported by an educational grant from Forest Pharmaceuticals, Inc.81
Page 1 and 2:
American Society of Hypertension201
Page 3 and 4:
Valturna offers bothsuperior BP eff
Page 5 and 6:
Figure 2: Probability of Achieving
Page 7 and 8:
potential for other drugs acting on
Page 9 and 10:
aliskiren arms were about one-third
Page 11 and 12:
As with other drugs that block angi
Page 13:
American Society of Hypertension201
Page 18:
Program Color KeyThe pages of this
Page 21 and 22:
General InformationThis program boo
Page 23 and 24:
General Information continuedHilton
Page 25 and 26:
General Information continuedASH Sc
Page 27 and 28:
General Information continuedASH Hy
Page 29 and 30:
2010 ASH Corporate MembersBoehringe
Page 31 and 32: ASH Leadership2009-2010 Board of Di
Page 33 and 34: Special LectureMonday, May 3, 2010,
Page 35 and 36: Special LectureMonday, May 3, 2010,
Page 37 and 38: 2010 Abstract Reviewers continuedEr
Page 39 and 40: Visit TEKTURNA at Booth 1100.and/or
Page 41 and 42: 5.5 HyperkalemiaIncreases in serum
Page 43 and 44: with Pgp substrates or weak to mode
Page 45 and 46: ASH Program at a GlanceSaturday, Ma
Page 47 and 48: ASH Program at a GlanceMonday, May
Page 49 and 50: Poster Category PresentationPosters
Page 51 and 52: 2010 ASH Faculty continuedJeffrey R
Page 53 and 54: 2010 ASH Faculty continuedAndrew Wh
Page 55 and 56: 2010American Societyof Hypertension
Page 57 and 58: Saturday Afternoon MAY 1PostersPost
Page 59 and 60: Saturday Afternoon MAY 1Sessions3:3
Page 61 and 62: Saturday Afternoon MAY 1Sessions3:3
Page 63 and 64: Sunday Morning MAY 2Satellite Sympo
Page 65 and 66: Sunday Morning MAY 2Sessions contin
Page 67 and 68: Sunday Morning MAY 2Sessions8:00 AM
Page 69 and 70: Sunday Morning MAY 2Sessions10:00 A
Page 71 and 72: Sunday Morning MAY 2Sessions10:00 A
Page 73 and 74: Sunday Afternoon MAY 2Sessions3:30
Page 75 and 76: Sunday Afternoon MAY 2Sessions3:30
Page 77 and 78: Sunday Afternoon MAY 2Special Sessi
Page 79 and 80: Sunday Evening MAY 2Sessions6:00 PM
Page 81: Sunday Evening MAY 2Sessions6:00 PM
Page 85 and 86: Monday Morning MAY 3Sessions8:00 AM
Page 87 and 88: Monday Morning Afternoon MAY 21 3Po
Page 89 and 90: Monday Morning MAY 3Sessions10:00 A
Page 95 and 96: Monday Evening May 3Satellite Sympo
Page 97 and 98: Tuesday Morning May 48:45 AM LB-OR-
Page 99 and 100: Tuesday Morning May 4Sessions8:00 A
Page 101 and 102: Tuesday Morning MAY 4ASH Membership
Page 103 and 104: Tuesday Morning MAY 4Sessions10:55
Page 105 and 106: 2010American Societyof Hypertension
Page 107 and 108: Saturday Afternoon MAY 1Posters3:00
Page 109 and 110: Saturday Afternoon MAY 1PostersPO-2
Page 125 and 126: Sunday Morning MAY 2PostersPosters
Page 127 and 128: Sunday Morning MAY 2Posters9:00 AM
Page 129 and 130: Sunday Morning MAY 2PostersPO-123:
Page 131 and 132: Sunday Morning MAY 2PostersPO-137:
Page 133 and 134:
Sunday Morning MAY 2PostersPO-150:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Monday Morning Afternoon MAY 21 3Po
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Monday Morning Afternoon May 213Pos
Page 163 and 164:
Faculty Disclosure ListingGail Adle
Page 165 and 166:
Faculty Disclosure Listing continue
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
you to attend thethe Innovations Th
Page 175 and 176:
5.5 HyperkalemiaIncreases in serum
Page 177 and 178:
with Pgp substrates or weak to mode
Page 179 and 180:
Valturna (aliskiren and valsartan,
Page 181 and 182:
4 CONTRAINDICATIONSNone.5 WARNINGS
Page 183 and 184:
een reported. In a 4-day trial of v
Page 185 and 186:
7 DRUG INTERACTIONSNo drug interact
Page 187 and 188:
8.5 Geriatric UseIn 8.5the Geriatri
Page 189 and 190:
2010 ASH ExhibitorsASH Hypertension
Page 191 and 192:
ASH Hypertension Resource CenterHil
Page 193 and 194:
2010 ASH Exhibitors continuedCVRx I
Page 195 and 196:
2010 ASH Exhibitors continuedIntern
Page 197 and 198:
2010 ASH Exhibitors continuedNature
Page 199 and 200:
2010 ASH Exhibitors continuedRESPeR
Page 201 and 202:
Author IndexAAbaunza, Ricardo, 122A
Page 203 and 204:
Author IndexCastellano, Maurizio, 1
Page 205 and 206:
Author IndexGuarneri, Marco, 146Guo
Page 207 and 208:
Author IndexLekakis, John, 118, 122
Page 209 and 210:
Author IndexPittaras, Andreas, 149P
Page 211 and 212:
Author IndexTello, Susana, 109, 135
Page 213 and 214:
Hilton New York Floor PlansSecond F
Page 215 and 216:
Hilton New York Floor PlansFourth F
Page 218:
Are You 1in 3?Get the facts. Know y
show all

2010 Annual Scientific Meeting and Exposition 2010 Annual ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?